Pyridinyl-Tetrazole Hybrids as Potential Anticancer Agents: Synthesis, Bioactivity, and Computational Insights
Department
Chemistry
Advisor
Dr. Baker Jawabrah Al Hourani, PhD
Document Type
Poster
Start Date
2-26-2025 2:00 PM
End Date
2-26-2025 5:00 PM
Abstract
Chronic inflammation is a significant contributor to the development of diseases such as cancer, heart disease, and diabetes. The cyclooxygenase-2 (COX-2) enzyme plays a key role in the pro-inflammatory pathway, and NSAIDs are designed to target and regulate COX-2. Ongoing research in drug synthesis is crucial for developing compounds with enhanced binding affinity to COX-2. Nine pyridinyl-tetrazole hybrids can be synthesized by reacting specific amides with sodium azide and silicon tetrachloride at 90°C, with molar ratios of 1.0:17.0:4.0. After purification, these hybrids will undergo bioassays with cancer cell lines and computational studies to evaluate their binding affinity for COX-2. This study aims to identify potential drug candidates for inflammation-related diseases, with anti-proliferation results compared to a commercially available positive control.
Recommended Citation
Ostlie, Ben M., "Pyridinyl-Tetrazole Hybrids as Potential Anticancer Agents: Synthesis, Bioactivity, and Computational Insights" (2025). Day of Scholarship. 19.
https://spark.bethel.edu/dayofscholarship/spring2025/feb26/19
Pyridinyl-Tetrazole Hybrids as Potential Anticancer Agents: Synthesis, Bioactivity, and Computational Insights
Chronic inflammation is a significant contributor to the development of diseases such as cancer, heart disease, and diabetes. The cyclooxygenase-2 (COX-2) enzyme plays a key role in the pro-inflammatory pathway, and NSAIDs are designed to target and regulate COX-2. Ongoing research in drug synthesis is crucial for developing compounds with enhanced binding affinity to COX-2. Nine pyridinyl-tetrazole hybrids can be synthesized by reacting specific amides with sodium azide and silicon tetrachloride at 90°C, with molar ratios of 1.0:17.0:4.0. After purification, these hybrids will undergo bioassays with cancer cell lines and computational studies to evaluate their binding affinity for COX-2. This study aims to identify potential drug candidates for inflammation-related diseases, with anti-proliferation results compared to a commercially available positive control.
